OUTLOOK THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.78 USD | +6.14% |
|
+2.64% | -1.27% |
Presenter SpeechJenene Thomas (Attendees)Good afternoon, and thank you for joining us for the ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Calendar
2024-08-13
- Q3 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.78
USD
Average target price
39.86
USD
Spread / Average Target
+412.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.27% | 182M | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Transcript : Outlook Therapeutics, Inc. - Special Call
